Research Paper Volume 15, Issue 11 pp 4963—4985
FDX1 serves as a prognostic biomarker and promotes glioma progression by regulating the immune response
Figure 9. Silencing FDX1 inhibits glioma progression via the NOD1-PDL1 axis. (A) qRT-PCR shows low PDL1 expression after FDX1 silencing. (B) NOD1 and PDL1 levels are upregulated in FDX1-silenced cells after NOD1-C treatment. (C, D) Key molecules of migration decreased after FDX1 silencing. (E) Wound closure ratio elevated in FDX1-silenced cells. (F, G) Number of migrating and invading tumor cells increased in FDX1-silenced cells after NOD1-C treatment.